AngioDynamics, Inc. (NASDAQ:ANGO) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research firms have also recently issued reports on ANGO. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Barclays PLC cut their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 19th. Cantor Fitzgerald increased their target price on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $17.00 target price on shares of AngioDynamics in a research report on Tuesday, July 18th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $18.50.

Shares of AngioDynamics (NASDAQ ANGO) traded up 0.29% during mid-day trading on Friday, hitting $17.10. The stock had a trading volume of 459,833 shares. The stock’s 50-day moving average is $16.28 and its 200 day moving average is $16.18. AngioDynamics has a 12 month low of $14.80 and a 12 month high of $18.18. The company has a market cap of $625.52 million, a PE ratio of 124.82 and a beta of 1.15.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.03. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The firm had revenue of $86.90 million during the quarter, compared to analysts’ expectations of $90.72 million. During the same quarter last year, the business posted $0.19 earnings per share. The firm’s revenue was down 7.0% on a year-over-year basis. On average, equities research analysts forecast that AngioDynamics will post $0.67 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “AngioDynamics, Inc. (ANGO) Upgraded to “Hold” by BidaskClub” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/19/angiodynamics-inc-ango-upgraded-to-hold-by-bidaskclub.html.

In other news, CEO James C. Clemmer purchased 20,000 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was acquired at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the acquisition, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at approximately $1,355,722.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Clemmer purchased 5,000 shares of the business’s stock in a transaction on Friday, July 21st. The shares were purchased at an average price of $15.79 per share, with a total value of $78,950.00. Following the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at $1,368,724.57. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,316 shares of company stock valued at $396,806 in the last 90 days. 1.88% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue boosted its position in AngioDynamics by 91.7% in the second quarter. State of Alaska Department of Revenue now owns 6,768 shares of the medical instruments supplier’s stock valued at $109,000 after buying an additional 3,238 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its position in AngioDynamics by 77.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 3,100 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in AngioDynamics by 3.0% in the first quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock valued at $125,000 after buying an additional 210 shares in the last quarter. Mason Street Advisors LLC boosted its position in AngioDynamics by 8.5% in the first quarter. Mason Street Advisors LLC now owns 7,470 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 584 shares in the last quarter. Finally, Acrospire Investment Management LLC boosted its position in AngioDynamics by 3.7% in the second quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock valued at $145,000 after buying an additional 317 shares in the last quarter. Institutional investors and hedge funds own 89.19% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.